Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith L Davis

Showing results (81-90 of 82) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 82 results.
The Oncologist|November 19, 2024
Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanomaJeffrey Weber, Waqas Haque, Svetomir N Markovic, et al.
Blood Advances|August 16, 2022
Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphomaGilles Salles, Stephen J Schuster, Martin Dreyling, et al.
Pageof 9

Showing results (81-90 of 82) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 82 results.
The Oncologist|November 19, 2024
Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanomaJeffrey Weber, Waqas Haque, Svetomir N Markovic, et al.
Blood Advances|August 16, 2022
Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphomaGilles Salles, Stephen J Schuster, Martin Dreyling, et al.
Pageof 9